SRPT Sarepta Therapeutics Inc.

Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial results before the NASDAQ Global Market opens on Thursday, October 27, 2016. Subsequently, at 8:00 a.m., Eastern Time, Edward Kaye, M.D., Sarepta’s chief executive officer, Sandy Mahatme, Sarepta’s chief financial officer, and Bo Cumbo, Sarepta’s senior vice president of global commercial development will host a conference call to discuss third quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 7029987. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2016 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

EN
24/10/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sarepta Therapeutics Inc.

Sarepta Therapeutics Inc: 1 director

A director at Sarepta Therapeutics Inc bought 37,038 shares at 133.801USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch